Barclays PLC Sells 509,134 Shares of Grifols, S.A. (NASDAQ:GRFS)

Barclays PLC reduced its stake in shares of Grifols, S.A. (NASDAQ:GRFS - Free Report) by 85.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 83,418 shares of the biotechnology company's stock after selling 509,134 shares during the quarter. Barclays PLC's holdings in Grifols were worth $621,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently added to or reduced their stakes in the business. GAMMA Investing LLC lifted its stake in Grifols by 44.5% in the fourth quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company's stock valued at $37,000 after acquiring an additional 1,527 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Grifols by 5.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 33,200 shares of the biotechnology company's stock valued at $247,000 after acquiring an additional 1,657 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Grifols by 10.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 25,867 shares of the biotechnology company's stock valued at $192,000 after acquiring an additional 2,403 shares during the last quarter. R Squared Ltd acquired a new stake in Grifols in the fourth quarter valued at approximately $28,000. Finally, HighTower Advisors LLC raised its position in shares of Grifols by 28.3% in the fourth quarter. HighTower Advisors LLC now owns 17,866 shares of the biotechnology company's stock valued at $133,000 after purchasing an additional 3,936 shares during the period.

Analyst Ratings Changes

Separately, Morgan Stanley began coverage on shares of Grifols in a research report on Wednesday, February 12th. They issued an "overweight" rating on the stock.

Check Out Our Latest Stock Report on GRFS

Grifols Stock Performance

Shares of NASDAQ:GRFS traded down $0.01 during trading on Tuesday, reaching $7.72. The stock had a trading volume of 307,940 shares, compared to its average volume of 1,187,229. Grifols, S.A. has a 52 week low of $5.79 and a 52 week high of $9.96. The firm has a market capitalization of $5.31 billion, a price-to-earnings ratio of 6.60 and a beta of 0.44. The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11. The stock has a fifty day simple moving average of $7.32 and a two-hundred day simple moving average of $7.64.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.

Featured Stories

• Five stocks we like better than Grifols
• 3 Must-Buy Warren Buffett Stocks for Volatile Times
• NuScale Power in Rebound Mode With Short-Squeeze a Possibility
• What Investors Need to Know to Beat the Market
• Qualcomm Is 5x Cheaper Than AMD, but Won’t Be for Long
• Financial Services Stocks Investing
• 3 Huge S&P 500 Winners From Trump Trade Deal & The Biggest Loser

Should You Invest $1,000 in Grifols Right Now?

Before you consider Grifols, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grifols wasn't on the list.

While Grifols currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report